(PharmaNewsWire.Com, March 17, 2017 ) Biosimilars or follow-on biologics are generic versions of the biopharmaceutical products. These are developed following the patent expiry of an original molecule. Biosimilars have the same biological properties as original drugs and target the same diseases. They have many similarities but are not identical to the reference biopharmaceutical product.
Publisher's analysts forecast the spending on the global monoclonal antibody (mAb) biosimilars market to grow at a CAGR of 4-7% during the period 2015-2020. For more information about this report http://www.reportsweb.com/global-mab-biosimilars-market-2016-2020 Covered in this report The report covers the present scenario and the growth prospects of the global monoclonal antibody (mAb) biosimilars market 2016-2020. To calculate the market size, the report considers the report considers the revenue generated from the sales of mAbs. The report also considers the revenues generated from the sales of drugs that are expected to be launched during the forecast period.
The market is divided into the following segments based on geography: - Europe - Asia - ROW
Publisher's report, Global Monoclonal Antibody (mAb) Biosimilars Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
